GlassScriptPhysician profile
Debora S Johnson
NPI 1205964269
$695.08
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $193 · 2021: $220 · 2022: $68.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $161.49 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $155.32 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $97.66 | 2019-2022 | |
| Abbvie INC. | $89.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $65.97 | 2019-2021 | |
| Lundbeck LLC | $33.65 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $27.18 | 2022 | |
| Sunovion Pharmaceuticals INC. | $25.89 | 2020 | |
| Alkermes, INC. | $21.96 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.02 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.